Aytu Biopharma Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
150
- Stock Symbol
-
AYTU
- Investments
-
11
- Share Price
-
$2.34
- (As of Friday Closing)
Aytu Biopharma General Information
Description
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
Contact Information
- 7900 East Union Avenue
- Suite 920
- Denver, CO 80237
- United States
Aytu Biopharma Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.34 | $2.29 | $1.38 - $4.88 | $13M | 5.57M | 165K | -$6.15 |
Aytu Biopharma Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2023 30-Jun-2023 | FY 2022 30-Jun-2022 | FY 2021 30-Jun-2021 |
|---|---|---|---|---|
| EV | 8,289 | 14,753 | 20,265 | 106,401 |
| Revenue | 101,843 | 107,399 | 96,669 | 65,632 |
| EBITDA | (15,726) | (9,651) | (99,489) | (50,330) |
| Net Income | (24,470) | (17,051) | (108,779) | (58,289) |
| Total Assets | 132,888 | 136,463 | 137,623 | 265,668 |
| Total Debt | 16,119 | 16,361 | 18,188 | 24,782 |
Aytu Biopharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aytu Biopharma Comparisons
Industry
Financing
Details
000000
000000
Aytu Biopharma Competitors (6)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ironshore Therapeutics | Venture Capital-Backed | 00 | 00000 | 000000000 | 00000 | |
| 00000000 | Corporation | Basel, Switzerland | 000000 | 0000 | 000000000 | 0000 |
| 000000 00000000000 | Corporation | Tokyo, Japan | 00000 | 0000 | 000000000 | 0000 |
| 0000000 000000 | Formerly VC-backed | Ewing, NJ | 000 | 00000 | 000000&0 | 00000 |
| 0000000 000000 000 | Venture Capital-Backed | Titusville, NJ | 00000 | 000000 - 000 |
Aytu Biopharma Patents
Aytu Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3171318-A1 | Oral compositions for bladder regulation and uses thereof | Pending | 29-Jul-2021 | 00000000000 | |
| US-11534474-B1 | Oral compositions for bladder regulation and uses thereof | Active | 29-Jul-2021 | 00000000000 | 0 |
| US-20160313296-A1 | Use of orp for characterizing stroke patients | Inactive | 21-Apr-2015 | 000000000000 | |
| AU-2015353639-B2 | Determination of fertility potential from the oxidation-reduction potential of a biological sample | Inactive | 25-Nov-2014 | 000000000000 | |
| AU-2015353639-A1 | Determination of fertility potential from the oxidation-reduction potential of a biological sample | Active | 25-Nov-2014 | G01N33/48707 |
Aytu Biopharma Executive Team (10)
Aytu Biopharma Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| John Donofrio | Self | Board Member | 000 0000 |
| Joshua Disbrow | Aytu Biopharma | Chief Executive Officer & Chairman | 000 0000 |
| Michael Macaluso | Aytu Biopharma | Board Member | 000 0000 |
| Steven Boyd | Self | Board Member | 000 0000 |
| Vivian Liu | Aytu Biopharma | Board Member | 000 0000 |
Aytu Biopharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Aytu Biopharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Aytu Biopharma Investments & Acquisitions (11)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Rumpus Therapeutics | 12-Apr-2021 | 0000000000 | 0000 | Drug Discovery | 000000 00 |
| Neos Therapeutics | 19-Mar-2021 | 0000000000 | 000.00 | Drug Discovery | 000000 00 |
| Innovus Pharmaceuticals | 14-Feb-2020 | 0000000000 | 000.00 | Pharmaceuticals | 000000 00 |
| Cerecor (Pediatric Portfolio) | 01-Nov-2019 | 000000000 | 000.00 | Buildings and Property | |
| Tris Pharma (Tuzistra XR) | 02-Nov-2018 | Corporate Asset Purchase | Buildings and Property | 000000 00 |
Aytu Biopharma ESG
Risk Overview
Risk Rating
Updated August, 31, 2020
15.3 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,042
Rank
Percentile
Consumer Services
Industry
00 of 434
Rank
Percentile
Consumer Services
Subindustry
00 of 120
Rank
Percentile
Aytu Biopharma Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| FSC Pediatrics (Primsol Business) | 31-Oct-2015 | 000000000000000000 | 00.000 | Completed |
|